GLPwatch
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
NCT05670379 · Completed
Last updated 2026-05-28This clinical trial is testing the safety, tolerability, and drug levels of an exenatide implant in adults who are overweight, have obesity, or type 2 diabetes.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 24 people
Who can join Ages 18–55 · all sexes Healthy volunteers accepted.
Timeline Started 2024-12 · est. completion 2025-08
Where 1 site · Australia
What this study is testing ClinicalTrials.gov NCT05670379 ↗
Description as written by the study sponsor.
The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.
Treatments tested
- Exenatide Implant also known as NPM115/NPM119 Combination Product
Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.
- Bydureon BCise (exenatide extended release) Drug
glucagon-like peptide-1 (GLP-1) receptor agonist
- Semaglutide, 1.0 mg/mL also known as Wegovy, Ozempic Drug
glucagon-like peptide-1 (GLP-1) receptor agonist
| Main thing measured | Area under the plasma concentration-time curve (AUC) |
|---|---|
| Sponsor | Vivani Medical, Inc |
| Conditions studied | Overweight and Obesity, Type2diabetes |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05670379 ↗